News

Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration

SAN DIEGO–(BUSINESS WIRE)– Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to entrectinib “for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies.” Entrectinib is the company’s investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor NTRK1/2/3, ROS1, or ALK gene fusions.

2017-06-27T12:21:17+00:00